NRx Pharmaceuticals Reports Q2 Results, FDA Ketamine Progress, and DARPA Selection
NRXP sits 97% above its 52-week low of $1.62.
Summary
NRx Pharmaceuticals reported Q2 2026 results with FDA ketamine ANDA progress, DARPA selection for NRX-101 trial, and a cash runway of at least one year.
Key Events · Earnings and Guidance · NRXP
-
FDA Ketamine ANDA Clears First Cycle
FDA completed first-cycle review of the ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item, a manufacturer's attestation on the vial, has been submitted to FDA.
-
Commercial Manufacturing Underway
Initiation of commercial scale manufacturing of preservative-free ketamine building to launch stock of 5 million doses, targeting commercialization in 2026.
-
DARPA Selects NRx for SPARC-TMS Trial
Selected by DARPA as prime contractor for SPARC-TMS, an FDA-approved Phase 2/3 trial of NRX-101 with robotic TMS. Anticipated non-dilutive funding exceeds $11.5 million.
-
Cash Runway Extended to One Year
Cash and cash equivalents of $26.7 million as of June 30, 2026, up from $7.8 million at year-end 2025. Management expects existing cash to fund operations for at least one year.
Analysis · NRXP · Life Sciences
NRx Pharmaceuticals delivered a pivotal Q2 update: the FDA completed its first-cycle review of the preservative-free ketamine ANDA with no drug-related major deficiencies, and the company has submitted the sole remaining attestation. Commercial manufacturing is underway for a 5-million-dose launch stock, targeting 2026 commercialization. The company was also selected by DARPA as prime contractor for a Phase 2/3 trial of NRX-101, with over $11.5 million in anticipated non-dilutive funding. Financially, the six-month net loss narrowed to $18.0 million from $23.1 million, and cash stands at $26.7 million, which management says funds operations for at least a year. These developments materially de-risk the ketamine approval path and expand the NRX-101 market opportunity, while the cash runway removes near-term survival concerns.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRXP was trading at $3.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $137.2M. The 52-week trading range was $1.62 to $5.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.